Hypochondroplasia
11
5
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (11)
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
An Interventional Study of Infigratinib in Children With Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
C-Type Natriuretic Peptide and Achondroplasia